Compugen establishes mAb development facility
TEL AVIV, Israel—Compugen Ltd. recently announced the establishment of a new facility in South San Francisco for the development of oncology and immunology monoclonal antibody (mAb) drug candidates. Compugen Inc., a wholly owned subsidiary of Compugen Ltd., will translate Compugen Ltd.'s growing portfolio of novel mAb targets into drug candidates for licensing and partnering. Dr. Mary Haak-Frendscho will serve as executive chairperson of the new subsidiary, and Dr. John J. Hunter will serve as the vice president of Antibody R&D and Site Head.
"We are at a pivotal moment where Compugen's unique Monoclonal Antibody Targets Discovery Platform is delivering high- quality, novel mAb targets … We enthusiastically look forward to leveraging the commercial potential of these pioneering and industry-leading predictive discovery capabilities," said Dr. Anat Cohen-Dayag, president and CEO of Compugen Ltd.